FDA approves bluebird bio’s Skysona to treat cerebral adrenoleukodystrophy
Pharmaceutical Technology
SEPTEMBER 19, 2022
The latest development is based on findings from the single-arm, open-label Phase II/III ALD-102 (Starbeam) and Phase III ALD-104 clinical trials. Mucositis, vomiting, nausea, febrile neutropenia, alopecia and reduced appetite among others were reported to be the most prevalent non-laboratory adverse reactions reported.
Let's personalize your content